Targeted treatments in advanced renal cell carcinoma

Focus on Axitinib

Elena Verzoni, Paolo Grassi, Isabella Testa, Roberto Iacovelli, Pamela Biondani, Enrico Garanzini, Filippo De Braud, Giuseppe Procopio

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer cell. Axitinib is a third-generation inhibitor of vascular endothelial growth factor receptor and is currently being developed for the treatment of various malignancies. The pharmacokinetic properties of axitinib may have a selective therapeutic effect, with minimal adverse reactions and enhanced safety. In a large Phase III study of previously treated patients with metastatic renal cell carcinoma, axitinib achieved a longer progression-free survival than sorafenib with an acceptable safety profle and good quality of life. This review focuses on the pharmacology, pharmacokinetics, and clinical activity of axitinib in the current treatment of renal cell carcinoma. The role of axitinib in the adjuvant and/or neoadjuvant setting needs to be evaluated in further clinical trials.

Original languageEnglish
Pages (from-to)107-116
Number of pages10
JournalPharmacogenomics and Personalized Medicine
Volume7
Issue number1
DOIs
Publication statusPublished - Mar 27 2014

Fingerprint

Renal Cell Carcinoma
Pharmacokinetics
Therapeutics
Safety
Vascular Endothelial Growth Factor Receptor
Angiogenesis Inhibitors
Clinical Pharmacology
Therapeutic Uses
United States Food and Drug Administration
Disease-Free Survival
Quality of Life
axitinib
Clinical Trials
Neoplasms

Keywords

  • Angiogenesis
  • Axitinib
  • Renal cell carcinoma
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Targeted treatments in advanced renal cell carcinoma : Focus on Axitinib. / Verzoni, Elena; Grassi, Paolo; Testa, Isabella; Iacovelli, Roberto; Biondani, Pamela; Garanzini, Enrico; De Braud, Filippo; Procopio, Giuseppe.

In: Pharmacogenomics and Personalized Medicine, Vol. 7, No. 1, 27.03.2014, p. 107-116.

Research output: Contribution to journalArticle

Verzoni, Elena ; Grassi, Paolo ; Testa, Isabella ; Iacovelli, Roberto ; Biondani, Pamela ; Garanzini, Enrico ; De Braud, Filippo ; Procopio, Giuseppe. / Targeted treatments in advanced renal cell carcinoma : Focus on Axitinib. In: Pharmacogenomics and Personalized Medicine. 2014 ; Vol. 7, No. 1. pp. 107-116.
@article{be010027a6eb451d95c81f579fbb0a38,
title = "Targeted treatments in advanced renal cell carcinoma: Focus on Axitinib",
abstract = "Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer cell. Axitinib is a third-generation inhibitor of vascular endothelial growth factor receptor and is currently being developed for the treatment of various malignancies. The pharmacokinetic properties of axitinib may have a selective therapeutic effect, with minimal adverse reactions and enhanced safety. In a large Phase III study of previously treated patients with metastatic renal cell carcinoma, axitinib achieved a longer progression-free survival than sorafenib with an acceptable safety profle and good quality of life. This review focuses on the pharmacology, pharmacokinetics, and clinical activity of axitinib in the current treatment of renal cell carcinoma. The role of axitinib in the adjuvant and/or neoadjuvant setting needs to be evaluated in further clinical trials.",
keywords = "Angiogenesis, Axitinib, Renal cell carcinoma, Vascular endothelial growth factor receptor",
author = "Elena Verzoni and Paolo Grassi and Isabella Testa and Roberto Iacovelli and Pamela Biondani and Enrico Garanzini and {De Braud}, Filippo and Giuseppe Procopio",
year = "2014",
month = "3",
day = "27",
doi = "10.2147/PGPM.S37098",
language = "English",
volume = "7",
pages = "107--116",
journal = "Pharmacogenomics and Personalized Medicine",
issn = "1178-7066",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Targeted treatments in advanced renal cell carcinoma

T2 - Focus on Axitinib

AU - Verzoni, Elena

AU - Grassi, Paolo

AU - Testa, Isabella

AU - Iacovelli, Roberto

AU - Biondani, Pamela

AU - Garanzini, Enrico

AU - De Braud, Filippo

AU - Procopio, Giuseppe

PY - 2014/3/27

Y1 - 2014/3/27

N2 - Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer cell. Axitinib is a third-generation inhibitor of vascular endothelial growth factor receptor and is currently being developed for the treatment of various malignancies. The pharmacokinetic properties of axitinib may have a selective therapeutic effect, with minimal adverse reactions and enhanced safety. In a large Phase III study of previously treated patients with metastatic renal cell carcinoma, axitinib achieved a longer progression-free survival than sorafenib with an acceptable safety profle and good quality of life. This review focuses on the pharmacology, pharmacokinetics, and clinical activity of axitinib in the current treatment of renal cell carcinoma. The role of axitinib in the adjuvant and/or neoadjuvant setting needs to be evaluated in further clinical trials.

AB - Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer cell. Axitinib is a third-generation inhibitor of vascular endothelial growth factor receptor and is currently being developed for the treatment of various malignancies. The pharmacokinetic properties of axitinib may have a selective therapeutic effect, with minimal adverse reactions and enhanced safety. In a large Phase III study of previously treated patients with metastatic renal cell carcinoma, axitinib achieved a longer progression-free survival than sorafenib with an acceptable safety profle and good quality of life. This review focuses on the pharmacology, pharmacokinetics, and clinical activity of axitinib in the current treatment of renal cell carcinoma. The role of axitinib in the adjuvant and/or neoadjuvant setting needs to be evaluated in further clinical trials.

KW - Angiogenesis

KW - Axitinib

KW - Renal cell carcinoma

KW - Vascular endothelial growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=84898745413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898745413&partnerID=8YFLogxK

U2 - 10.2147/PGPM.S37098

DO - 10.2147/PGPM.S37098

M3 - Article

VL - 7

SP - 107

EP - 116

JO - Pharmacogenomics and Personalized Medicine

JF - Pharmacogenomics and Personalized Medicine

SN - 1178-7066

IS - 1

ER -